Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions

Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and pharmacologic profile versus first-generation Sabril, targeting rare epilepsies.

Phase 2 expansion includes POC studies in photosensitive seizures, treatment-resistant FOS, TSC-associated seizures, and infantile spasms, with key catalysts in 2026-2027. Strong cash position, bolstered by warrant exercises and private placement, funds operations into 2029, supporting clinical advancement.

The last time I spoke about Ovid Therapeutics ( OVID ), it was with a Seeking Alpha article entitled " Ovid Therapeutics: OV329 Promising For Neuronal Excitability In Neurological Disorders ." With respect to this article, I mentioned that the company